Boehringer, Lilly creep up on Sanofi with Lantus biosimilar

Eli Lilly ($LLY) and Boehringer Ingelheim say their in-development Lantus biosimilar proved safe and effective as its reference treatment across 6 clinical trials. The two intend to launch the drug overseas when Sanofi's insulin comes off patent next year, but pending litigation could prolong a U.S. debut until 2016. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.